Thousands of patients suffering from advanced bladder cancer in the UK could experience significantly extended survival rates, potentially doubling their lifespan, thanks to a new 'groundbreaking' treatment recently approved by the NHS. Health authorities have hailed this development as 'one of the most hopeful advances in decades' for individuals battling the disease. This approval marks the first major shift in the treatment of stage 4 bladder cancer, which accounts for one in ten cases, since the 1980s.

The innovative treatment involves a combination of two powerful drugs: enfortumab, an antibody drug, and pembrolizumab, an immunotherapy drug. This regimen received approval from the National Institute for Health and Care Excellence (NICE). Clinical trials demonstrated remarkable efficacy, with patients receiving the combined treatment living for an average of nearly three years, a stark contrast to the 16 months seen in those on standard, platinum-based chemotherapy. Furthermore, patients on the new treatment showed a progression-free survival time of one year, compared to just six months for those receiving conventional care.

Beyond extending lives, the treatment also proved highly effective in eradicating cancer. Three in ten patients on the combined therapy had no evidence of cancer remaining, significantly higher than the 14.5 per cent observed in patients undergoing standard care. Martyn Hewett, a 75-year-old from Stratford, east London, is one such beneficiary. After a failed surgery to remove his tumours, he received the treatment at Barts Health NHS Trust. He credits the trial with saving his life, stating, 'If I hadn't been on this trial, I imagine I would be dead now.' He expressed gratitude for the extra years it has given him to see his grandson grow up.

Administered via IV infusion, the treatment is designed for patients whose cancer has metastasized throughout their body and cannot be surgically removed. Enfortumab vedotin works by directly targeting and killing cancer cells, while pembrolizumab boosts the immune system, enabling it to recognize and combat any residual cancer cells. A key advantage of this new therapy is the experience of fewer harmful side effects compared to traditional treatments.

Experts have consistently highlighted an 'unmet need' for patients with advanced, metastatic bladder cancer, noting that only 29 per cent of those diagnosed with stage four live for a year. This new combination therapy addresses that critical gap. It is estimated that approximately 1,250 people annually could benefit from this life-changing treatment. Professor Peter Johnson, NHS England's national clinical director for cancer, emphasized that the therapy will help thousands live longer, providing them with more precious moments with loved ones. Helen Knight, director of medicines evaluation at NICE, praised the drug's effectiveness, stating it could make a 'tremendous difference to the length and quality of people's lives.' Dr. Timir Patel, medical director of Astellas UK, which manufactures enfortumab vedotin, affirmed that this combination therapy will redefine the standard of care for advanced bladder cancer patients.